BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 29753029)

  • 1. Inherited Genetic Variants Associated with Melanoma BRAF/NRAS Subtypes.
    Thomas NE; Edmiston SN; Orlow I; Kanetsky PA; Luo L; Gibbs DC; Parrish EA; Hao H; Busam KJ; Armstrong BK; Kricker A; Cust AE; Anton-Culver H; Gruber SB; Gallagher RP; Zanetti R; Rosso S; Sacchetto L; Dwyer T; Ollila DW; Begg CB; Berwick M; Conway K;
    J Invest Dermatol; 2018 Nov; 138(11):2398-2404. PubMed ID: 29753029
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Associations of MC1R Genotype and Patient Phenotypes with BRAF and NRAS Mutations in Melanoma.
    Thomas NE; Edmiston SN; Kanetsky PA; Busam KJ; Kricker A; Armstrong BK; Cust AE; Anton-Culver H; Gruber SB; Luo L; Orlow I; Reiner AS; Gallagher RP; Zanetti R; Rosso S; Sacchetto L; Dwyer T; Parrish EA; Hao H; Gibbs DC; Frank JS; Ollila DW; Begg CB; Berwick M; Conway K;
    J Invest Dermatol; 2017 Dec; 137(12):2588-2598. PubMed ID: 28842324
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
    Ekedahl H; Cirenajwis H; Harbst K; Carneiro A; Nielsen K; Olsson H; Lundgren L; Ingvar C; Jönsson G
    Br J Dermatol; 2013 Nov; 169(5):1049-55. PubMed ID: 23855428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Polymorphisms in nevus-associated genes MTAP, PLA2G6, and IRF4 and the risk of invasive cutaneous melanoma.
    Kvaskoff M; Whiteman DC; Zhao ZZ; Montgomery GW; Martin NG; Hayward NK; Duffy DL
    Twin Res Hum Genet; 2011 Oct; 14(5):422-32. PubMed ID: 21962134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical characteristics associated with BRAF, NRAS and KIT mutations in Japanese melanoma patients.
    Sakaizawa K; Ashida A; Uchiyama A; Ito T; Fujisawa Y; Ogata D; Matsushita S; Fujii K; Fukushima S; Shibayama Y; Hatta N; Takenouchi T; Uehara J; Okuyama R; Yamazaki N; Uhara H
    J Dermatol Sci; 2015 Oct; 80(1):33-7. PubMed ID: 26282084
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Association Between NRAS and BRAF Mutational Status and Melanoma-Specific Survival Among Patients With Higher-Risk Primary Melanoma.
    Thomas NE; Edmiston SN; Alexander A; Groben PA; Parrish E; Kricker A; Armstrong BK; Anton-Culver H; Gruber SB; From L; Busam KJ; Hao H; Orlow I; Kanetsky PA; Luo L; Reiner AS; Paine S; Frank JS; Bramson JI; Marrett LD; Gallagher RP; Zanetti R; Rosso S; Dwyer T; Cust AE; Ollila DW; Begg CB; Berwick M; Conway K;
    JAMA Oncol; 2015 Jun; 1(3):359-68. PubMed ID: 26146664
    [TBL] [Abstract][Full Text] [Related]  

  • 7. NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.
    Uguen A; Talagas M; Costa S; Samaison L; Paule L; Alavi Z; De Braekeleer M; Le Marechal C; Marcorelles P
    Diagn Pathol; 2015 Jul; 10():121. PubMed ID: 26204954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Characterization of genetic alterations in primary human melanomas carrying BRAF or NRAS mutation].
    Lázár V
    Magy Onkol; 2013 Jun; 57(2):96-9. PubMed ID: 23795354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between BRAFV600E and NRASQ61R mutations and clinicopathologic characteristics, risk factors and clinical outcome of primary invasive cutaneous melanoma.
    Wu S; Kuo H; Li WQ; Canales AL; Han J; Qureshi AA
    Cancer Causes Control; 2014 Oct; 25(10):1379-86. PubMed ID: 25048604
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Melanoma brain metastases harboring BRAF
    Fang P; Boehling NS; Koay EJ; Bucheit AD; Jakob JA; Settle SH; Brown PD; Davies MA; Sulman EP
    J Neurooncol; 2018 Mar; 137(1):67-75. PubMed ID: 29198052
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heterogeneity of BRAF, NRAS, and TERT Promoter Mutational Status in Multiple Melanomas and Association with MC1R Genotype: Findings from Molecular and Immunohistochemical Analysis.
    Pellegrini C; Di Nardo L; Cipolloni G; Martorelli C; De Padova M; Antonini A; Maturo MG; Del Regno L; Strafella S; Micantonio T; Leocata P; Peris K; Fargnoli MC
    J Mol Diagn; 2018 Jan; 20(1):110-122. PubMed ID: 29061376
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prevalence of BRAF, NRAS and c-KIT mutations in Slovenian patients with advanced melanoma.
    Moltara ME; Novakovic S; Boc M; Bucic M; Rebersek M; Zadnik V; Ocvirk J
    Radiol Oncol; 2018 Apr; 52(3):289-295. PubMed ID: 30210039
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.
    Carlino MS; Haydu LE; Kakavand H; Menzies AM; Hamilton AL; Yu B; Ng CC; Cooper WA; Thompson JF; Kefford RF; O'Toole SA; Scolyer RA; Long GV
    Br J Cancer; 2014 Jul; 111(2):292-9. PubMed ID: 24918823
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinicopathological characteristics and mutation profiling in primary cutaneous melanoma.
    Yaman B; Akalin T; Kandiloğlu G
    Am J Dermatopathol; 2015 May; 37(5):389-97. PubMed ID: 25357015
    [TBL] [Abstract][Full Text] [Related]  

  • 15. NRAS and BRAF mutations in melanoma-associated nevi and uninvolved nevi.
    Tschandl P; Berghoff AS; Preusser M; Burgstaller-Muehlbacher S; Pehamberger H; Okamoto I; Kittler H
    PLoS One; 2013; 8(7):e69639. PubMed ID: 23861977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The molecular profile of metastatic melanoma in Australia.
    Lyle M; Haydu LE; Menzies AM; Thompson JF; Saw RP; Spillane AJ; Kefford RF; Mann GJ; Cooper WA; Yu B; Scolyer RA; O'Toole SA; Long GV
    Pathology; 2016 Feb; 48(2):188-93. PubMed ID: 27020391
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BRAF and NRAS mutations and antitumor immunity in Korean malignant melanomas and their prognostic relevance: Gene set enrichment analysis and CIBERSORT analysis.
    Min KW; Choe JY; Kwon MJ; Lee HK; Kang HS; Nam ES; Cho SJ; Park HR; Min SK; Seo J; Kim YJ; Kim NY; Kim HY
    Pathol Res Pract; 2019 Dec; 215(12):152671. PubMed ID: 31630873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRAF(V600E) and NRAS(Q61L/Q61R) mutation analysis in metastatic melanoma using immunohistochemistry: a study of 754 cases highlighting potential pitfalls and guidelines for interpretation and reporting.
    Kakavand H; Walker E; Lum T; Wilmott JS; Selinger CI; Smith E; Saw RP; Yu B; Cooper WA; Long GV; O'Toole SA; Scolyer RA
    Histopathology; 2016 Oct; 69(4):680-6. PubMed ID: 27151331
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mutations in the BRAF, NRAS, and C-KIT Genes of Patients Diagnosed with Melanoma in Colombia Population.
    Gutiérrez-Castañeda LD; Gamboa M; Nova JA; Pulido L; Tovar-Parra JD
    Biomed Res Int; 2020; 2020():2046947. PubMed ID: 32775409
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The BRAF and NRAS mutation prevalence in dermoscopic subtypes of acquired naevi reveals constitutive mitogen-activated protein kinase pathway activation.
    Tan JM; Tom LN; Jagirdar K; Lambie D; Schaider H; Sturm RA; Soyer HP; Stark MS
    Br J Dermatol; 2018 Jan; 178(1):191-197. PubMed ID: 28714107
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.